METHODS AND PRODUCTS FOR TREATMENT OF DISEASES
The invention provides a method of treating a disease or condition mediated by vascular hyperpermeability in an animal. The method comprises administering an amount of a danazol compound effective to inhibit vascular hyperpermeability and an amount of a second drug effective to treat the disease or condition. The invention further provides a method of inhibiting vascular hyperpermeability when it is a side effect caused by administration of a drug to, or another treatment of, an animal. The method comprises administration of an amount of a danazol compound effective to inhibit the vascular hyperpermeability. The invention also provides a method of modulating the cytoskeleton of endothelial cells in an animal comprising administering an amount of a danazol compound and an amount of a second drug effective to modulate the cytoskeleton. The present invention also relates to pharmaceutical compositions and kits comprising a danazol compound and a second drug.
1 - 45 . (canceled)
46 . A kit comprising a first container and a second container, wherein the first container comprises danzol or a pharmaceutically-acceptable salt thereof in an amount between 1 mg and 100 mg, and the second container comprises an angiotensin converting enzyme (ACE) inhibitor drug or an ACE receptor antagonist drug suitable for treating a disease or condition mediated by vascular hyperpermeability.
47 .- 62 . (canceled)
63 . The kit of claim 46 , wherein the ACE inhibitor or ACE receptor antagonist is selected from the group consisting of captopril, lisinopril, enalapril, benazepril, ramipril, quinapril, fosinopril, trandolapril, perindopril, an S1P agonist and moexipril.
64 . The kit of claim 63 , wherein the S1P agonist is fingolimod.
65 . The kit of claim 46 , wherein the ACE inhibitor or ACE receptor antagonist is enalapril.
66 . The kit of claim 46 , wherein the ACE inhibitor or ACE receptor antagonist is lisinopril.
67 . A pharmaceutical composition comprising a pharmaceutically-acceptable carrier, danazol or a pharmaceutically-acceptable salt thereof in an amount between 1 mg and 100 mg, and a drug that is an angiotensin converting enzyme (ACE) inhibitor or an ACE receptor antagonist drug.
68 . The pharmaceutical compositions of claim 67 , wherein the ACE inhibitor or ACE inhibitor antagonist is selected from the group consisting of captopril, lisinopril, enalapril, benazepril, ramipril, quinapril, fosinopril, trandolapril, perindopril, an S1P agonist and moexipril.
69 . The pharmaceutical composition of claim 68 , wherein the S1P agonist is fingolimod.
70 . The pharmaceutical composition of claim 67 , wherein the ACE inhibitor or ACE inhibitor antagonist is enalapril.
71 . The pharmaceutical composition of claim 67 , wherein the ACE inhibitor or ACE inhibitor antagonist is lisinopril.